Meeting
2021 ASCO Annual Meeting
Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.
Authors
Lori J. Wirth
Massachusetts General Hospital Cancer Center, Boston, MA
Lori J. Wirth , Eric Jeffrey Sherman , Daniela Weiler , Maria E. Cabanillas , Bruce Robinson , Antoine Italiano , Janessa J. Laskin , Vivek Subbiah , Alexander E. Drilon , Victoria Soldatenkova , Pearl Plernjit French , Jennifer Wright , Matthias Kroiss , Manisha H. Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT03157128
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6074)
DOI
10.1200/JCO.2021.39.15_suppl.6074
Abstract #
6074
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.
First Author: Aaron Scott Mansfield
Poster
2021 ASCO Annual Meeting
A pooled analysis of response to selective RET inhibitors among patients with medullary thyroid cancer with M918T versus non-M918T RET mutations.
First Author: Janice Kim
Poster
2021 ASCO Annual Meeting
Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.
First Author: Eric Jeffrey Sherman
Poster
2020 ASCO Virtual Scientific Program
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
First Author: Manisha H. Shah